文献速递心力衰竭与心肌病冠心病血脂与心血管预防

心衰、2型糖尿病与慢性肾脏病复杂共病管理中的错失机会:一项回顾性队列研究

Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study.
PubMed 文献 · Heart · 2025-07-28

该研究利用英国临床实践研究数据链(1998-2020)评估161 529例心衰、慢性肾脏病或2型糖尿病患者在出现第二种共病前后对指南推荐标准的依从性。结果显示肾素-血管紧张素系统抑制剂、β受体阻滞剂、抗血小板药和他汀的处方率欠佳,高龄、女性、外周动脉疾病和癌症与血压、肌酐和糖化血红蛋白检查率降低相关。结论认为重叠共病的指南推荐诊疗不理想,存在年龄、性别、首诊疾病和共病带来的不平等。

要点

  • 心衰、CKD和T2D重叠患者中指南推荐药物处方率欠佳。
  • 高龄、女性、外周动脉疾病和癌症与相关检查率降低相关。
  • 以心衰为首诊与T2D诊断后HbA1C测量几率降低相关(OR 0.79)。

核心结论

  • 在心衰、慢性肾脏病和2型糖尿病重叠的患者中,指南推荐诊疗不理想,并存在按年龄、性别、首诊疾病和共病的不平等。
  • 质量改进需要跨疾病的数据联动采集、监测和行动。

研究设计与样本

  • 回顾性队列研究,使用英国临床实践研究数据链(1998-2020)。
  • 纳入161 529例心衰、慢性肾脏病或2型糖尿病患者,评估出现第二种共病前后的诊疗依从性。
  • 分析疾病检查率、药物使用及指南依从性的预测因素。

主要发现

  • CKD+HF、CKD+T2D和HF+T2D组分别占40%、51.3%和8.6%,第二次诊断后中位随访3.1年。
  • CKD+HF、CKD+T2D和HF+T2D组的RAS抑制剂处方率分别为71%、64.1%和74.4%。
  • 上述三组的β受体阻滞剂处方率分别为53.1%、36.2%和55.1%。
  • 上述三组的抗血小板药处方率分别为56.2%、45.2%和54.4%,他汀处方率分别为56.7%、68.5%和72%。
  • 高龄、女性、外周动脉疾病和癌症分别与心衰、CKD和T2D诊断后血压、肌酐和HbA1C检查几率降低相关;以心衰为首诊与T2D诊断后HbA1C测量几率降低相关(OR 0.79,95%CI 0.72-0.86)。

临床怎么用

  • 对心衰、CKD和T2D重叠患者应主动评估指南推荐药物(RAS抑制剂、β受体阻滞剂、抗血小板药、他汀)的使用情况。
  • 关注高龄、女性、外周动脉疾病和癌症患者,减少检查与治疗不足。
  • 跨疾病联动管理,定期监测血压、肌酐和HbA1C。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2D) is critical, yet evidence of adherence to guideline-recommended standards in routine care remains unclear. We aimed to assess primary care adherence to guideline-recommended standards for patients with overlapping HF, CKD and T2D in England. METHODS: Using UK Clinical Practice Research Datalink (1998-2020), we evaluated care adherence across 161 529 individuals with HF, CKD or T2D before and after developing a second of these conditions. We analysed disease investigation rates, medication use and predictors of guideline adherence. RESULTS: We identified 161 529 patients with CKD followed by HF (CKD+HF, 40%), CKD+T2D (51.3%) and HF+T2D (8.6%) with a median of 3.1 years follow-up after the second diagnosis. In CKD+HF, CKD+T2D and HF+T2D groups, prescription rates of renin-angiotensin system inhibitors (71%, 64.1% and 74.4%), beta-blockers (53.1%,36.2% and 55.1%), antiplatelets (56.2%, 45.2% and 54.4%) and statins (56.7%, 68.5% and 72%) were suboptimal. Advanced age, female sex, peripheral arterial disease and cancer were associated with a lower likelihood of checking blood pressure, creatinine and glycated haemoglobin (HbA1C) after HF, CKD and T2D diagnoses, respectively. The first diagnosis of HF was associated with reduced odds of having HbA1C measured after T2D diagnosis (OR 0.79, 95% CI 0.72 to 0.86), compared with CKD as the first diagnosis. CONCLUSIONS: In overlapping HF, CKD and T2D, guideline-recommended care is suboptimal, with inequalities by age, sex, disease on first presentation and comorbidities. Quality improvement requires linked data collection, monitoring and action across diseases.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Pasea L, Mohamed M, Dashtban A, et al. Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study. Heart. 2025. PMID: 40037768. doi:10.1136/heartjnl-2024-325046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。